Ensilicated Technologies Ltd

EnsiliTech is a biotech startup applying its patented platform technology, to store and transport biologicals without refrigeration or freezing.

EnsiliTech is a recent biotech startup looking to apply their patented platform technology, Ensilication, to store and transport vaccines, antibodies, and other biopharmaceuticals, without the need for refrigeration or freezing. Having raised £1.2 million in an oversubscribed pre-seed round in December 2022, and with participation in numerous accelerator programmes, their mission is to deploy this technology across both human and animal healthcare sectors. Currently, the shipment and storage of biopharmaceuticals requires a continuous network of fridges and freezers known as the cold chain. This system is extremely costly to operate and prone to regular failures, resulting in over 50% of the vaccines being wasted. Globally, 1.5 million infants die each year from vaccine-preventable diseases, primarily in low-middle income countries, where vaccines struggle to be delivered. Ensilication is a novel method for encasing thermally unstable biomolecules within a silica network to prevent degradation at room temperature and improves the shelf-life. The technology is designed to be applied both to existing, and new biopharmaceutical formulations. It produces thermally stable products that do not rely on cold-chain transport and storage, presenting significant cost savings, reducing wastage, and increasing global accessibility to life-saving treatments and diagnostics.

• Biofuels
• Immunology/inflammation
• Diagnostics
• Platform Technology
• Virology
• Antimicrobial Resistance
• Autoimmune diseases
• Agricultural
• Oncology
• Enzyme